The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).
 
Changhoon Yoo
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Ipsen; MSD Oncology; SERVIER
Speakers' Bureau - Bayer; Celgene; Eisai; Ipsen; Merck Sharp & Dohme
Research Funding - AstraZeneca; Bayer; CKD pharm; SERVIER
 
Kyu-Pyo Kim
Travel, Accommodations, Expenses - Agios; Roche/Genentech
 
Ilhwan Kim
Honoraria - SERVIER
 
Myoung Joo Kang
No Relationships to Disclose
 
Jaekyung Cheon
No Relationships to Disclose
 
Byung Woog Kang
No Relationships to Disclose
 
Hyewon Ryu
No Relationships to Disclose
 
Jae Ho Jeong
No Relationships to Disclose
 
Ji Sung Lee
No Relationships to Disclose
 
Kyung Won Kim
No Relationships to Disclose
 
Baek-Yeol Ryoo
No Relationships to Disclose